Human Gene Therapy: Risks and Safety Considerations

Abstract

Gene therapy has long been perceived as a once‐in‐a‐lifetime treatment that can give life‐long benefits. Some potential risks have been underestimated or have not received sufficient attention.

Keywords: gene; disease; viral; therapy; safety; oncogenesis; virogenesis

Further Reading

Baum C, Dullmann J, Li Z et al. (2003) Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 101: 2099–2114 (Review).

Bushman FD (2003) Targeting survival: integration site selection by retroviruses and LTR‐retrotransposons. Cell 115: 135–138 (Review).

Cavazzana‐Calvo M, Hacein‐Bey S, de Saint Basile G et al. (2000) Gene therapy of human severe combined immunodeficiency (SCID)‐X1 disease. Science 288: 669–672.

Fox JL (2000) Gene‐therapy death prompts broad civil lawsuit. Nature Biotechnology 18: 1136.

Friedmann T (1997) Overcoming the obstacles to gene therapy. Scientific American 276: 96–101.

Hertig C, Coupar BE, Gould AR and Boyle DB (1997) Field and vaccine strains of fowlpox virus carry integrated sequences from the avian retrovirus, reticuloendotheliosis virus. Virology 235: 367–376.

Isfort R, Jones D, Kost R, Witter R and Kung HJ (1992) Retrovirus insertion into herpesvirus in vitro and in vivo. Proceedings of the National Academy of Sciences of the USA 89: 991–995.

Isfort RJ, Qian Z, Jones D et al. (1994) Integration of multiple chicken retroviruses into multiple chicken herpesviruses: herpesviral gD as a common target of integration. Virology 203: 125–133.

Jones D, Brunovskis P, Witter R and Kung HJ (1996) Retroviral insertional activation in a herpesvirus: transcriptional activation of US genes by an integrated long terminal repeat in a Marek's disease virus clone. Journal of Virology 70: 2460–2467.

Moore KM, Davis JR, Sato T and Yasuda A (2000) Reticuloendotheliosis virus (REV) long terminal repeats incorporated in the genomes of commercial fowl poxvirus vaccines and pigeon poxviruses without indication of the presence of infectious REV. Avian Diseases 44: 827–841.

Morgan RA and Blaese RM (1999) Gene therapy: lessons learned from the past decade. British Medical Journal 319: 1310.

Neil JC and Cameron ER (2002) Retroviral insertion sites and cancer: fountain of all knowledge? Cancer Cell 2: 253–255.

Thompson L (2000) Human gene therapy. Harsh lessons, high hopes. FDA Consumer 34(5) [http://www.fda.gov/fdac/features/2000/500_gene.html].

Thomas CE, Ehrhardt A and Kay MA (2003) Progress and problems with the use of viral vectors for gene therapy. Nature Review Genetics 4: 346–358 (Review).

Vadolas J, Williamson R and Ioannou PA (2002) Gene therapy for inherited lung disorders: an insight into pulmonary defence. Pulmonary Pharmacology and Therapeutics 15: 61–72 (Review).

Wu X, Li Y, Crise B and Burgess SM (2003) Transcription start regions in the human genome are favored targets for MLV integration. Science 300: 1749–1751.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Ioannou, Panos A, and Vadolas, Jim(Jan 2006) Human Gene Therapy: Risks and Safety Considerations. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1038/npg.els.0003946]